814 related articles for article (PubMed ID: 17329323)
21. Preclinical substantia nigra dysfunction in rapid eye movement sleep behaviour disorder.
Miyamoto M; Miyamoto T; Iwanami M; Muramatsu S; Asari S; Nakano I; Hirata K
Sleep Med; 2012 Jan; 13(1):102-6. PubMed ID: 22033122
[TBL] [Abstract][Full Text] [Related]
22. Increased substantia nigra echogenicity correlated with visual hallucinations in Parkinson's disease: a Chinese population-based study.
Li T; Shi J; Qin B; Fan D; Liu N; Ni J; Zhang T; Zhou H; Xu X; Wei M; Zhang X; Wang X; Liu J; Wang Y; Tian J
Neurol Sci; 2020 Mar; 41(3):661-667. PubMed ID: 31754876
[TBL] [Abstract][Full Text] [Related]
23. Substantia nigra echogenicity: A structural correlate of functional impairment of the dopaminergic striatal projection in Parkinson's disease.
Weise D; Lorenz R; Schliesser M; Schirbel A; Reiners K; Classen J
Mov Disord; 2009 Aug; 24(11):1669-75. PubMed ID: 19514075
[TBL] [Abstract][Full Text] [Related]
24. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings.
Berg D; Siefker C; Becker G
J Neurol; 2001 Aug; 248(8):684-9. PubMed ID: 11569897
[TBL] [Abstract][Full Text] [Related]
25. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound.
Berg D; Becker G; Zeiler B; Tucha O; Hofmann E; Preier M; Benz P; Jost W; Reiners K; Lange KW
Neurology; 1999 Sep; 53(5):1026-31. PubMed ID: 10496262
[TBL] [Abstract][Full Text] [Related]
26. Substantia nigra hyperechogenicity as a marker for Parkinson's disease: a population-based study.
Mahlknecht P; Seppi K; Stockner H; Nocker M; Scherfler C; Kiechl S; Willeit J; Schmidauer C; Gasperi A; Rungger G; Poewe W
Neurodegener Dis; 2013; 12(4):212-8. PubMed ID: 23689066
[TBL] [Abstract][Full Text] [Related]
27. Brainstem raphe and substantia nigra echogenicity in idiopathic REM sleep behavior disorder with comorbid depression.
Vilas D; Iranzo A; Pont-Sunyer C; Serradell M; Gaig C; Santamaria J; Tolosa E
J Neurol; 2015 Jul; 262(7):1665-72. PubMed ID: 25929659
[TBL] [Abstract][Full Text] [Related]
28. Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease.
Schweitzer KJ; Brüssel T; Leitner P; Krüger R; Bauer P; Woitalla D; Tomiuk J; Gasser T; Berg D
J Neurol; 2007 May; 254(5):613-6. PubMed ID: 17415511
[TBL] [Abstract][Full Text] [Related]
29. Substantia Nigra Echogenicity Associated with Clinical Subtypes of Parkinson's Disease.
Zhou HY; Huang P; Sun Q; Du JJ; Cui SS; Tan YY; Hu YY; Zhan WW; Wang Y; Xiao Q; Liu J; Chen SD
J Parkinsons Dis; 2018; 8(2):333-340. PubMed ID: 29614699
[TBL] [Abstract][Full Text] [Related]
30. Transcranial sonography in idiopathic REM sleep behavior disorder and multiple system atrophy.
Li X; Xue S; Jia S; Zhou Z; Qiao Y; Hou C; Wei K; Zheng W; Rong P; Jiao J
Psychiatry Clin Neurosci; 2017 Apr; 71(4):238-246. PubMed ID: 27898200
[TBL] [Abstract][Full Text] [Related]
31. Transcranial midbrain sonography and depressive symptoms in patients with Parkinson's disease.
Stanković I; Stefanova E; Žiropadja L; Mijajlović M; Pavlović A; Kostić VS
J Neurol; 2015 Mar; 262(3):689-95. PubMed ID: 25557281
[TBL] [Abstract][Full Text] [Related]
32. Substantia nigra echogenicity is correlated with nigrostriatal impairment in Machado-Joseph disease.
Pedroso JL; Bor-Seng-Shu E; Felício AC; Braga-Neto P; Hoexter MQ; Teixeira MJ; Bressan RA; Barsottini OG
Parkinsonism Relat Disord; 2013 Aug; 19(8):742-5. PubMed ID: 23680416
[TBL] [Abstract][Full Text] [Related]
33. Value of combined midbrain sonography, olfactory and motor function assessment in the differential diagnosis of early Parkinson's disease.
Busse K; Heilmann R; Kleinschmidt S; Abu-Mugheisib M; Höppner J; Wunderlich C; Gemende I; Kaulitz L; Wolters A; Benecke R; Walter U
J Neurol Neurosurg Psychiatry; 2012 Apr; 83(4):441-7. PubMed ID: 22362921
[TBL] [Abstract][Full Text] [Related]
34. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected].
Iranzo A; Lomeña F; Stockner H; Valldeoriola F; Vilaseca I; Salamero M; Molinuevo JL; Serradell M; Duch J; Pavía J; Gallego J; Seppi K; Högl B; Tolosa E; Poewe W; Santamaria J;
Lancet Neurol; 2010 Nov; 9(11):1070-7. PubMed ID: 20846908
[TBL] [Abstract][Full Text] [Related]
35. [Transcranial sonography of substantia nigra in patients with Parkinson's disease].
Miwa H
Rinsho Shinkeigaku; 2013; 53(11):981-2. PubMed ID: 24291852
[TBL] [Abstract][Full Text] [Related]
36. Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: no.
Walter U
J Neural Transm (Vienna); 2011 Apr; 118(4):607-12. PubMed ID: 21190047
[TBL] [Abstract][Full Text] [Related]
37. Midbrain transcranial sonography in Korean patients with Parkinson's disease.
Kim JY; Kim ST; Jeon SH; Lee WY
Mov Disord; 2007 Oct; 22(13):1922-6. PubMed ID: 17588240
[TBL] [Abstract][Full Text] [Related]
38. Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder.
Iranzo A; Stockner H; Serradell M; Seppi K; Valldeoriola F; Frauscher B; Molinuevo JL; Vilaseca I; Mitterling T; Gaig C; Vilas D; Santamaria J; Högl B; Tolosa E; Poewe W
Mov Disord; 2014 Dec; 29(14):1774-80. PubMed ID: 25384461
[TBL] [Abstract][Full Text] [Related]
39. Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson's disease.
Schweitzer KJ; Hilker R; Walter U; Burghaus L; Berg D
Mov Disord; 2006 Jan; 21(1):94-8. PubMed ID: 16114024
[TBL] [Abstract][Full Text] [Related]
40. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease.
Berg D; Merz B; Reiners K; Naumann M; Becker G
Mov Disord; 2005 Mar; 20(3):383-5. PubMed ID: 15486999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
